O T C
PAOG Target CBD Pharma Development In Puerto Rico Could Get Boost From COVID-19

Sandusky, OH – Sep 17, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today highlighted recent increased interest in the resurgence of industry-wide Pharmaceutical research and manufacturing in Puerto Rico. PAOG is currently in discussions in to engage a Contract Research Organization (CRO) in Puerto Rico to advance an Investigational New

PAOG Announces Agreement To Build Pharmaceutical Hemp Cultivar Facility On PURA Farmersville Site

Sandusky, OH – September 16, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced an agreement with Puration, Inc. (OTC PINK: PURA) to build a proprietary hemp cultivar development facility on PURA’s Farmersville, Texas branded site.    PAOG recently acquired a hemp cultivation business from PURA and is now expanding

PAOG Advances RespRx Research Into International CBD Pharma Research Arena

Sandusky, OH – Sep 15, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced an international research initiative to advance its hemp-derived cannabidiol (CBD) pharmaceutical treatment for Chronic Obstructive Pulmonary Disease (COPD). The COPD treatment, RespRx, is derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled

PAOG Goes Global With CBD Pharmaceutical Research To Target $5.8 Billion Market

Sandusky, OH – Sep 15, 2020 – OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) Announces a multifold, international research initiative to advance its hemp-derived cannabidiol (CBD) pharmaceutical treatment for Chronic Obstructive Pulmonary Disease (COPD). The COPD treatment, RespRx, is derived from a patented cannabis extraction method – U.S. Patent No. 9,199,960 entitled

PAOG Completes Compliance Updates In Conjunction With Cannabis Biopharma Revitalization Initiative

Sandusky, OH – August 27, 2020 –  OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today announced having published all required filings necessary to meet the OTC Markets “Current Information” reporting standard. Yesterday, the company published the final compliance requirement, a legal opinion, following the publications of its Q1 2020 and Q2 2020

PAOG Confirms Goldman Small Cap Research Report Expected Tomorrow

Sandusky, OH – August 12, 2020 –  OTC PR WIRE — PAO Group, Inc. (OTC PINK: PAOG) today confirmed the company has engaged Goldman Small Cap Research to provide ongoing analyst coverage. The initial report is anticipated to be published tomorrow, August 13, 2020. PAOG recently executed a management takeover followed by the acquisition of

PURA Announces 1 For 1 Stock Dividend Declaration

Dallas, TX – August 11, 2020 – OTC PR WIRE — Puration, Inc. (OTC PINK: PURA) today announced a declaration of a stock dividend. The planned dividend distribution to PURA shareholders results from the recent sale of PURA’s cannabis cultivation operation to PAO Group, Inc. (OTC PINK: PAOG). The company plans to promptly announce a

REPUBLIC OF SOUTH AFRICA MEDICAL MARIJUANA DISPENSARIES (RSAMMD) ANNOUNCES SUCCESSFUL TESTING RESULTS OF PROPRIETARY CANNABIS PLANT EXTRACTION TECHNOLOGY WITH JV PARTNER PROTEX PHARMA (TXTM)

Live Cannabis Plant Extraction into Highly Bioavailable, Non-psychoactive Cannabis Medicines Now Possible Johannesburg, South Africa–May 7th, 2020 – Republic of South Africa Medical Marijuana Dispensaries Pty Ltd. (RSAMMD) is pleased to announce the successful testing of its proprietary live cannabis plant extraction technology in conjunction with its joint venture partner, US-based Protext Pharma, Inc. (OTC

Immune Therapeutics, Inc. Focusing to Drive Shareholder Value

Winter Park, FL, May 6, 2020 —Immune Therapeutics, Inc. (OTC PINK: IMUN) (“Immune” “IMUN” or the “Company”) is a late-stage biopharmaceutical company focused on the development of T-cell activation immunotherapy to treat life-threatening or chronic diseases announced it has initiated a corporate plan to drive shareholder value. Recent economic events require that Immune revisit its

Immune Therapeutics, Inc. and Forte Biotechnology Intl Corp Sign Sub-Licensing Agreement for Animal Health Applications

Immune Therapeutics Announces Settlement with Major Creditors as part of licensing agreement Immune Therapeutics Announces Filing of 10K Extension Under SEC Allowance for COVID19 Disruption Forte Aims to Develop and Commercialize Lodonal and IRT=101 for the Treatment of Cancer and Inflammatory Disease in Companion Animals Orlando Florida April 16, 2020 – Immune Therapeutics Inc. (OTC

Contact Us

  • 707-OTC-WIRE (707-682-9473)
  • cs@otcprwire.com

All Rights Reserved © 2019